JAK1 and lung cancer: Further, AXL expression was associated with JAK1-STAT3 signaling in treatment-naïve tumors and lung cancer patient-derived organoids with high levels of AXL and JAK1 were sensitive to combined treatment with AXL kinase inhibitor TP-0903 and JAK inhibitor ruxolitinib [93].